TY - JOUR
T1 - Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis
AU - Cooper-Knock, Johnathan
AU - Moll, Tobias
AU - Ramesh, Tennore
AU - Castelli, Lydia
AU - Beer, Alexander
AU - Robins, Henry
AU - Fox, Ian
AU - Niedermoser, Isabell
AU - Van Damme, Philip
AU - Moisse, Matthieu
AU - Robberecht, Wim
AU - Hardiman, Orla
AU - Panades, Monica P.
AU - Assialioui, Abdelilah
AU - Mora, Jesus S.
AU - Basak, A. Nazli
AU - Morrison, Karen E.
AU - Shaw, Christopher E.
AU - Al-Chalabi, Ammar
AU - Landers, John E.
AU - Wyles, Matthew
AU - Heath, Paul R.
AU - Higginbottom, Adrian
AU - Walsh, Theresa
AU - Kazoka, Mbombe
AU - McDermott, Christopher J.
AU - Hautbergue, Guillaume M.
AU - Kirby, Janine
AU - Shaw, Pamela J.
PY - 2019/2/26
Y1 - 2019/2/26
N2 - Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disorder without effective neuroprotective therapy. Known genetic variants impair pathways, including RNA processing, axonal transport, and protein homeostasis. We report ALS-causing mutations within the gene encoding the glycosyltransferase GLT8D1. Exome sequencing in an autosomal-dominant ALS pedigree identified p.R92C mutations in GLT8D1, which co-segregate with disease. Sequencing of local and international cohorts demonstrated significant ALS association in the same exon, including additional rare deleterious mutations in conserved amino acids. Mutations are associated with the substrate binding site, and both R92C and G78W changes impair GLT8D1 enzyme activity. Mutated GLT8D1 exhibits in vitro cytotoxicity and induces motor deficits in zebrafish consistent with ALS. Relative toxicity of mutations in model systems mirrors clinical severity. In conclusion, we have linked ALS pathophysiology to inherited mutations that diminish the activity of a glycosyltransferase enzyme. Amyotrophic lateral sclerosis (ALS) is an incurable neurodegeneration. Cooper-Knock et al. report ALS-causing mutations within GLT8D1. Mutations are associated with the substrate binding site and impair enzyme activity. Mutated GLT8D1 is neurotoxic and induces an ALS-like zebrafish phenotype.
AB - Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disorder without effective neuroprotective therapy. Known genetic variants impair pathways, including RNA processing, axonal transport, and protein homeostasis. We report ALS-causing mutations within the gene encoding the glycosyltransferase GLT8D1. Exome sequencing in an autosomal-dominant ALS pedigree identified p.R92C mutations in GLT8D1, which co-segregate with disease. Sequencing of local and international cohorts demonstrated significant ALS association in the same exon, including additional rare deleterious mutations in conserved amino acids. Mutations are associated with the substrate binding site, and both R92C and G78W changes impair GLT8D1 enzyme activity. Mutated GLT8D1 exhibits in vitro cytotoxicity and induces motor deficits in zebrafish consistent with ALS. Relative toxicity of mutations in model systems mirrors clinical severity. In conclusion, we have linked ALS pathophysiology to inherited mutations that diminish the activity of a glycosyltransferase enzyme. Amyotrophic lateral sclerosis (ALS) is an incurable neurodegeneration. Cooper-Knock et al. report ALS-causing mutations within GLT8D1. Mutations are associated with the substrate binding site and impair enzyme activity. Mutated GLT8D1 is neurotoxic and induces an ALS-like zebrafish phenotype.
KW - amyotrophic lateral sclerosis
KW - cell model
KW - genetics
KW - GLT8D1
KW - glycosyltransferase
KW - zebrafish
UR - http://www.scopus.com/inward/record.url?scp=85061337780&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2019.02.006
DO - 10.1016/j.celrep.2019.02.006
M3 - Article
C2 - 30811981
AN - SCOPUS:85061337780
SN - 2211-1247
VL - 26
SP - 2298-2306.e5
JO - Cell Reports
JF - Cell Reports
IS - 9
ER -